NCT06390098View on ClinicalTrials.gov

Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51

PHASE1CompletedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

August 9, 2021

Primary Completion Date

October 12, 2021

Study Completion Date

October 12, 2021

Conditions

Healthy Participants

Interventions

DRUG

ASN51

Oral

Trial Locations (1)

Unknown

Hammersmith, London

Sponsors

Lead Sponsor

Asceneuron S.A.

All Listed Sponsors

collaborator

Hammersmith Medicines Research Invicro

UNKNOWN

lead

Asceneuron S.A.

INDUSTRY

NCT06390098 - Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51 | Biotech Hunter | Biotech Hunter